Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease

New England Journal of Medicine

Volumn 376, Issue 20, 2017, Pages 1933-1942

  Lincoff, A Michael ^a   Nicholls, Stephen J ^b   Riesmeyer, Jeffrey S ^d   Barter, Philip J ^c   Brewer, H Bryan ^e   Fox, Keith A A ^f   Gibson, C Michael ^g   Granger, Christopher ^h   Menon, Venu ^a   Montalescot, Gilles ⁱ   Rader, Daniel ^j   Tall, Alan R ^k   McErlean, Ellen ^a   Wolski, Kathy ^a   Ruotolo, Giacomo ^d   Vangerow, Burkhard ^d   Weerakkody, Govinda ^d   Goodman, Shaun G ^m   Conde, Diego ^p   McGuire, Darren K ^q   Nicolau, Jose C ^r   Leiva Pons, Jose L ^s   Pesant, Yves ⁿ   Li, Weimin ^t   Kandath, David ^l   Kouz, Simon ^o   Tahirkheli, Naeem ^u   Mason, Denise ^a   Nissen, Steven E ^a   more..

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d ELI LILLY AND COMPANY   (United States)

^e MEDSTAR RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF EDINBURGH   (United Kingdom)

^g BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁱ SORBONNE UNIVERSITÉ   (France)

^j Preventive Cardiovascular Medicine   (United States)

^k Howard Hughes Medical Institute   (United States)

^l Saratoga Associates   (United States)

^m ST MICHAEL'S HOSPITAL   (Canada)

ⁿ Recherche médicale Saint Jérôme Inc   (Canada)

^o Centre de Santé et de Services Sociaux du Nord de Lanaudière Centre Hospitalier Régional de Lanaud   (Canada)

^p INSTITUTO CARDIOVASCULAR DE BUENOS AIRES   (Argentina)

^q UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^r UNIVERSITY OF SÃO PAULO   (Brazil)

^s HOSPITAL CENTRAL DR IGNACIO MORONES PRIETO   (Mexico)

^t HARBIN MEDICAL UNIVERSITY   (China)

^u Oklahoma Heart Hospital   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EVACETRAPIB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; BENZODIAZEPINE DERIVATIVE; BIOLOGICAL MARKER; CHOLESTEROL ESTER TRANSFER PROTEIN; HYPOCHOLESTEROLEMIC AGENT;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; BASAL CELL CARCINOMA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL OUTCOME; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERIPHERAL VASCULAR DISEASE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; TORSADE DES POINTES; UNSTABLE ANGINA PECTORIS; VASCULAR DISEASE; AGED; ANTAGONISTS AND INHIBITORS; BLOOD; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; INTRACRANIAL ARTERIOSCLEROSIS; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PERIPHERAL VASCULAR DISEASES; RISK; TREATMENT FAILURE;

AGED; ANTICHOLESTEREMIC AGENTS; BENZODIAZEPINES; BIOMARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTRACRANIAL ARTERIOSCLEROSIS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PERIPHERAL VASCULAR DISEASES; RISK; TREATMENT FAILURE;

EID: 85019790381     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1609581     Document Type: Article

References (35)

1. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-81.
2. Fulcher J, O'Connell R, Voysey M, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015;385:1397-405.
3. Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol 2005;46:1225-8.
4. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk: the PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996;124:Suppl:S11-S20.
5. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA 1986;256:2835-8.
6. Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001;104:1108-13.
7. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301-10.
8. Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003;23:160-7.
9. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22.
10. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012;367:2089-99.
11. Nicholls SJ, Brewer HB, Kastelein JJ, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 2011;306:2099-109.
12. Nicholls SJ, Lincoff AM, Barter PJ, et al. Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: rationale and design of the ACCELERATE trial. Am Heart J 2015;170:1061-9.
13. Bhatt DL, Fox KAA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-17.
14. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
15. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57.
16. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15.
17. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129:Suppl 2:S1-45.
18. Thompson A, Di Angelantonio E, Sarwar N, et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA 2008;299:2777-88.
19. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012;380:572-80.
20. Ridker PM, Paré G, Parker AN, Zee RY, Miletich JP, Chasman DI. Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study. Circ Cardiovasc Genet 2009;2:26-33.
21. Holmes MV, Asselbergs FW, Palmer TM, et al. Mendelian randomization of blood lipids for coronary heart disease. Eur Heart J 2015;36:539-50.
22. Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000;406:203-7.
23. Nicholls SJ, Ruotolo G, Brewer HB, et al. Cholesterol efflux capacity and pre-beta-1 HDL concentrations are increased in dyslipidemic patients treated with evacetrapib. J Am Coll Cardiol 2015;66:2201-10.
24. Lüscher TF, Landmesser U, von Eckardstein A, Fogelman AM. High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target. Circ Res 2014;114:171-82.
25. Rosenson RS, Brewer HB Jr, Ansell BJ, et al. Dysfunctional HDL and atherosclerotic cardiovascular disease. Nat Rev Cardiol 2016;13:48-60.
26. Joy T, Hegele RA. Is raising HDL a futile strategy for atheroprotection? Nat Rev Drug Discov 2008;7:143-55.
27. Rohatgi A, Khera A, Berry JD, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med 2014;371:2383-93.
28. Saleheen D, Scott R, Javad S, et al. Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study. Lancet Diabetes Endocrinol 2015;3:507-13.
29. Nicholls SJ, Ruotolo G, Brewer HB, et al. Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients. J Clin Lipidol 2016;10:519-527.e4.
30. Yamashita S, Matsuzawa Y, Okazaki M, et al. Small polydisperse low density lipoproteins in familial hyperalphalipoproteinemia with complete deficiency of cholesteryl ester transfer activity. Atherosclerosis 1988;70:7-12.
31. Albert MA, Danielson E, Rifai N, Ridker PM, PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001;286:64-70.
32. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292:1307-16.
33. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35.
34. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
35. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387-97.